Patients in Cuba will have better access to therapy for lymphoma and rheumatoid arthritis

28.06.2018

Patients in Cuba will have better access to therapy for lymphoma and rheumatoid arthritis

The Ministry of Health of the Republic of Cuba (CECMED) has approved biosimilar rituximab developed by BIOCAD, a Russian biotech company. First supplies of the BIOCAD's rituximab are scheduled for late 2018, and market analysts expect it to make the treatment of lymphomas and rheumatoid arthritis more affordable for the Cuban patients.

More Category: Media release
Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients

28.06.2018

Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients

In March 2018, BIOCAD analyzed results from its Phase II study in which the original Russian IL-17 inhibitor proved highly effective in long-term therapy in patients with severe psoriasis. The drug also showed great results in the treatment of ankylosing spondylitis.

More Category: Media release
Russian infliximab biosimilar has been proved equivalent to Remicade® in international clinical trials

20.02.2018

Russian infliximab biosimilar has been proved equivalent to Remicade® in international clinical trials

BIOCAD has now completed the international clinical studies of infliximab biosimilar in ankylosing spondylitis and has finished the main phase of the international clinical study in rheumatoid arthritis. All studies were conducted in direct comparison with Remicade®. The therapeutic effects of the BIOCAD's infliximab biosimilar have been shown equivalent to the effects of the originator, and the safety profiles of two drugs were similar even in the long-term. BIOCAD ran its clinical studies of the infliximab biosimilar in compliance with the most recent international guidelines including the EMA's guidelines on non-clinical and clinical investigation of similar biological medicinal products containing monoclonal antibodies.

More Category: Media release
Cancer Research as Art: BIOCAD demonstrated the use of HeLa cells in oncology research

18.12.2017

Cancer Research as Art: BIOCAD demonstrated the use of HeLa cells in oncology research

unTOUCHABLE ART, Russia’s first sociocultural trip, was held in Saint-Petersburg in December. BIOCAD, a biotechnology company, demonstrated how “immortal” HeLa cells are used all over the world in oncology research and in development of anti-cancer drugs. The “IMMORTAL” installation devoted to the first ever cell line is part of a new science-art project that displays cancer research technologies.

More Category: Media release
Russian biotechnology company BIOCAD prepares to enters the European market

30.10.2017

Russian biotechnology company BIOCAD prepares to enters the European market

The largest Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines. So far, there are seven molecules in the European portfolio of BIOCAD. This are innovative and biosimilar products, which could be used in treatment of melanoma, breast, stomach, kidney and lung cancer, rheumatoid arthritis, psoriasis and multiple sclerosis.

More Category: Media release